Research programme: antibody therapeutics - University of California Los Angeles/Xencor
Latest Information Update: 11 May 2021
At a glance
- Originator University of California at Los Angeles; Xencor
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified